PROG

Biora Therapeutics, Inc. (PROG) | Rumor.io

Biora Therapeutics

PROG

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about PROG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% new	0% 0

Sep 3

Biora Therapeutics, Inc. (PROG) has received top analyst ratings and price targets for the week.
The specific ratings and targets are not mentioned in the available information.
The post is focused on PROG as the main subject being discussed.

Generated by AI

Sentiment

Of the messages about PROG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100%	35.56% -36.37
Bearish	—	0%	0%	64.44% +36.37

Bullish· Mar 29

$PROG has shown strong support at $1.20, with volume increasing and price starting to climb, despite a disappointing earnings call.
The stock has a high potential for a V-shaped recovery, with a possible move above the yellow resistance zone and a Fibonacci 0.50 area.
There have been significant blocks of shares purchased in $PROG, indicating strong buying interest and potential for future growth.

Bearish· Dec 29

$PROG has been heavily shorted due to poor management and its pre-clinical status, with many investors holding onto this narrative despite the company's fundamentals.
The lack of PR and news from the company, combined with a bearish market and omicron scare, have contributed to the stock's decline.
$PROG's poor performance is attributed to a combination of factors, including a lack of catalysts, a weak chart, and a possible pump and dump scheme, with many investors expressing concern about the stock's value.

Generated by AI

Topics

Of the messages about PROG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	20%
Announcements	—	—	—	80%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Nov 11

Biora Therapeutics, Inc. (PROG) reported an EPS loss of $0.38, which was lower than the expected loss of $0.48.
The company's earnings report was seen as a disappointment by some, with one post calling out investors who sold their shares after the report, saying they were "a fucking idiot" for not understanding the play.
The report was also seen as a positive step forward, with one post stating that the future is "VERY BRIGHT" and that potential partners are in place, although no specific names were mentioned.

Analysts· Oct 14

HC Wainwright initiates coverage of Biora Therapeutics, Inc. (PROG) with a "buy" rating and a price target of $4.
The price target of $4 is a significant upgrade from the company's previous offering price of $1.50.
Analyst Joseph Pantginis at HC Wainwright initiates coverage of PROG with a Buy rating and a price target of $4.

Announcements· Jan 26

Progenity, Inc. (Biora Therapeutics, Inc.) has strengthened its intellectual property for single-molecule detection technology with an additional patent.
The patent is material to the company's single-molecule detection platform under development.
The additional patent strengthens Progenity's intellectual property in the single-molecule detection technology space.

Technical Analysis· Mar 24

$PROG is trading near a key resistance level on the 10-minute chart, with a volume of 3.65.
The stock is currently consolidating in a bull pennant on the 20-minute chart, holding the 1.62 level, and has a volume of 2.1MM.
The RSI and MACD indicators are both rising, indicating a bullish trend, but may be approaching overbought levels.

Generated by AI

Community

Of the messages about PROG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	3.33%
Newcomers	—	100%	100%	96.67%

Regulars· May 10

The FDA may not require Biora Therapeutics to collect all the data they are planning, which could support an accelerated device approval.
The company's Q1 report is due, and the name change to Biora Therapeutics is now official.
Biora Therapeutics' quarterly revenue growth rate has declined by 95.8% YoY, ranking 4083 out of 5738 companies in the database.

Newcomers· Mar 29

Many newcomers are focused on the recent 21% drop in Biora Therapeutics, Inc. (PROG), wondering if it's deserved and if it's a buying opportunity.
New investors are also discussing the high volume of shares traded on PROG, with some attributing it to spoofing, blocktrading, and naked shorts.
Some newcomers are hoping for a buyout or short squeeze, with one investor doubling down on PROG, citing the company's $88 million in cash and partnerships with Big Pharma.

Generated by AI

Also Discussed

Investors talking about PROG also mention

#	Name	Attention
1	METX - Meten Holding Group Ltd.	——
2	Vinco Ventures Inc.BBIG	0%+0
3	Aterian Inc.ATER	0%new
4	SDC - SmileDirectClub, Inc.	——
5	Longeveron Inc. Class A Common StockLGVN	0%0
6	BIOR - Biora Therapeutics, Inc.	——
7	CEI - Camber Energy, Inc.	——
8	Farmmi, Inc. Class A Ordinary SharesFAMI	0%0
9	PTPI - Petros Pharmaceuticals, Inc.	——
10	IRNT - IronNet, Inc.	——